Skip links

For Healthcare Providers

What is MIRA™?

MIRA™ assesses a combination of miRNA biomarkers in order to determine the status of a patient’s endometrial receptivity, increasing the chances of IVF treatment success.

Request Information

How can MIRA™ help?

There are many factors contributing to a successful IVF cycle. One of these is identifying the optimal time (or window of implantation) for embryo implantation. By analyzing the endometrium’s tissue through genetic testing, MIRA™ identifies each patient’s window of implantation, providing you and your patients with a personalized recommendation for future embryo transfers.

Note:Patent Application No.: 62/869,574

Learn more

The optimal time for embryo transfer varies among individuals

Large scale studies have shown that 30% of infertility patients have a displaced window of implantation (WOI). MIRA™ is able to assess endometrial receptivity to determine the optimal time for embryo transfer.

Note:Courtesy of Katzorke, N et al. “Diagnosis of Endometrial-Factor Infertility: Current Approaches and New Avenues for Research.”

Geburtshilfe und Frauenheilkunde vol. 76,6 (2016): 699-703. doi:10.1055/s-0042-103752

Benefits of using MIRA™

70%

Reduced IVF Treatment Cycles

Transferring the embryo at the right time can decrease the overall number of IVF treatment cycles needed before obtaining a successful pregnancy.

Stable and Sensitive miRNA Biomarkers

MIRA™ can provide high-quality test results even with low sample amounts or low-quality samples. This reduces the fail rate and the need for resampling by more than 50% compared to other technologies.

Faster Turnaround Time

With decentralized testing, MIRA™’s service can be performed directly onsite, shortening the turnaround time to as little as one-third of the time of competing technologies.

What can MIRA™ tell you?

MIRA™ analyzes the endometrial biopsy and identifies the optimal implantation time so that you can perform a personalized embryo transfer during your patient’s next treatment cycle.

  Receptive: Best Time to Implant

In the Window of Implantation (WOI)
A Receptive result on the report indicates that the time of the tissue biopsy was the optimal time for embryo transfer and that the same conditions and timing can be used during their subsequent treatment cycles for the most favorable personalized embryo transfer conditions.

 Non-receptive: Adjust Implantation Time

NOT in the Window of Implantation (WOI)
A Non-Receptive result on the report indicates that the time of the tissue biopsy was not in the optimal time period for embryo transfer and that the timing of embryo transfer for the patient should be altered in order to increase the chances of a successful implantation.

Inconclusive: The analysis was not able to determine the optimal time for embryo transfer. This could be the result of an exceptionally low quality or low quantity biopsy sample. A MIRA™ representative will follow up with you to discuss altering the steps of the biopsy in order to retest your patient for a more comprehensive result. An inconclusive result happens in less than 1% of results.

Who should I recommend this test to?

Infertility patients that…

  • Have had multiple implantation failures
  • Are undergoing IVF treatment for the first time
  • Are over the age of 35
Download Brochure

When do I perform the MIRA™ biopsy during an IVF treatment cycle?

MIRA™ is compatible with both Natural Cycles and Hormone Replacement Therapy Cycles

NC: Day 7 after LH Surge or hCG Administration
HRT: Day 5 after Progesterone Administration

LH: Luteinizing Hormone Surge

MIRA™ Sample Submission Process

This simple procedure can be done directly at your fertility clinic. A MIRA™ sample submission kit is included to provide the tools needed for collecting an endometrial biopsy sample for the analysis.

Complete the Forms

Fill out the Sample Submission Form and ask the patient to complete the Consent Form (included in the kit).

Schedule the Biopsy

Endometrial biopsy should be scheduled based on either natural cycles or hormone replacement therapy cycles*.

Obtain the Sample

Place the endometrial biopsy in the MIRA™ cryotube. Ensure that the sample is immersed in the preservation solution.

Store the Sample

Label the MIRA™ cryotube with sample details and store the tube at 4°C for at least 4 hours.

Ship the Sample

Ship the package at room temperature to the designated shipping address using priority or next day shipping.

Note:
Endometrial biopsy should be taken either:
After 5 days (120 hours) of progesterone administration in a hormone replacement therapy (HRT) cycle. Or, after 7 days (168 hours) from hCG administration in a natural cycle.

Interested to find out more?

Contact Us